2026-08-29T20:41:51Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202242024-11-28T23:45:09Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16980
Repisalud author Balaguer, Catalina author Peralta, Alejandro author Rios, Angel author Iglesias, Amanda author Lluis Valera, Josep author Noguera, Aina author Soriano, Joan B author Agusti, Alvar author Sala Llinàs, Ernest 2024-07-09T09:12:55Z 2024-07-09T09:12:55Z 2016-04 Balaguer C, Peralta A, Rios Olivencia A, Iglesias A, Valera Felices JL, Noguera A, et al. Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. Contemp Clin Trials Commun. 2016 Apr;2:91-6. 10.1016/j.conctc.2015.12.008 2451-8654 Contemporary Clinical Trials Communications http://hdl.handle.net/20.500.13003/17303 29736450 L608628682 2-s2.0-84960154283 http://hdl.handle.net/20.500.12105/20224 399159100013 Introduction: Statins may have pleiotropic effects in COPD, but mechanisms remain unclear. Objectives: To assess the pleiotropic effect of statins in patients with stable COPD on (1): lung function (2); pulmonary and systemic inflammation (3); endothelial function (vascular stiffness) and circulating vascular growth factors; and (4), serum uric acid levels. Method: Pilot, double-blind, randomized, placebo-controlled clinical trial in 24 patients with stable COPD, all statin-naive, who were randomized (1: 1) to receive simvastatin 40 mg/24 h during 12 weeks (n = 12; 69.0 +/- 7.3 years; post-bd FEV1 53.4 +/- 10.0% pred.) or placebo (n = 12; 66.4 +/- 4.6 years; post-bd FEV1 48.2 +/- 12.6% pred.). Nine patients per group (total n = 18) completed the study. Results: Lung function, pulmonary and systemic inflammatory markers and the degree of vascular stiffness did not change significantly in any group. However, treatment with simvastatin increased the plasma levels of erythropoietin (Epo) (4.2 +/- 2.2 mIU/mL to 6.8 +/- 3.2 mlU/mL, p < 0.05) and reduced those of serum uric acid (7.1 +/- 1.3 mg/dL to 6.5 +/- 1.4 mg/dL, p < 0.01). Conclusions: Short-term treatment with simvastatin in stable COPD patients did not modify lung function, pulmonary and systemic inflammation, or vascular stiffness, but it changed Epo and uric acid levels. eng Statins COPD Inflammation Uric acid Erythropoietin Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial research article